Back to top
more

Assertio (ASRT)

(Delayed Data from NSDQ)

$0.71 USD

0.71
135,077

0.00 (-0.49%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $0.70 -0.01 (-1.75%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

New Strong Sell Stocks for July 8th

by Zacks Equity Research

ASRT, BLIN and BAH have been added to the Zacks Rank #5 (Strong Sell) List on July 8, 2025.

Zacks Equity Research

New Strong Sell Stocks for June 30th

by Zacks Equity Research

AEG, APOG and ASRT have been added to the Zacks Rank #5 (Strong Sell) List on June 30, 2025.

Zacks Equity Research

New Strong Sell Stocks for June 25th

by Zacks Equity Research

ASRT, BLIN and AMKR have been added to the Zacks Rank #5 (Strong Sell) List on June 25 2025.

Zacks Equity Research

New Strong Sell Stocks for June 18th

by Zacks Equity Research

APLE, ASRT and BOOT have been added to the Zacks Rank #5 (Strong Sell) List on June 18, 2025.

Zacks Equity Research

Assertio (ASRT) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Assertio (ASRT) delivered earnings and revenue surprises of -133.33% and 5.23%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

OmniAb, Inc. (OABI) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

OmniAb, Inc. (OABI) delivered earnings and revenue surprises of 0% and 11.50%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Journey Medical (DERM) Surges 9.1%: Is This an Indication of Further Gains?

by Zacks Equity Research

Journey Medical (DERM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Assertio (ASRT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Assertio (ASRT) delivered earnings and revenue surprises of -175% and 7.54%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 7.69% and 0.83%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

New Strong Buy Stocks for December 10th

by Zacks Equity Research

CTV, GRAB, ASRT, POWL and LUV have been added to the Zacks Rank #1 (Strong Buy) List on December 10, 2024.

Zacks Equity Research

New Strong Buy Stocks for November 29th

by Zacks Equity Research

MKTAY, ASRT, CHH, DRS and BRKL have been added to the Zacks Rank #1 (Strong Buy) List on November 29, 2024.

Zacks Equity Research

Assertio (ASRT) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Assertio (ASRT) delivered earnings and revenue surprises of 40% and 0.29%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Assertio (ASRT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Assertio (ASRT) delivered earnings and revenue surprises of -100% and 2.51%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

ARS Pharmaceuticals, Inc. (SPRY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Earnings Preview: Assertio (ASRT) Q2 Earnings Expected to Decline

by Zacks Equity Research

Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Revolution Medicines (RVMD) Moves 11.0% Higher: Will This Strength Last?

by Zacks Equity Research

Revolution Medicines (RVMD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Assertio (ASRT) Stock Plunges 65% in 3 Months: Here's Why

by Zacks Equity Research

Assertio (ASRT) appears weighed down by the recent leadership transition. The company is also facing challenges with sales of its product franchisee of late.

Zacks Equity Research

Assertio (ASRT) Shares Fall as Dan Peisert Steps Down as CEO

by Zacks Equity Research

Assertio (ASRT) appoints Heather Mason as its interim CEO as its current CEO, Dan Peisert, steps down from his role. Shares of the company fall on the same.

Sushmita Sarker headshot

Is the Options Market Predicting a Spike in Assertio (ASRT) Stock?

by Sushmita Sarker

Investors need to pay close attention to Assertio (ASRT) stock based on the movements in the options market lately.

Zacks Equity Research

Is the Options Market Predicting a Spike in Assertio (ASRT) Stock?

by Zacks Equity Research

Investors need to pay close attention to Assertio (ASRT) stock based on the movements in the options market lately.

Zacks Equity Research

Assertio (ASRT) Q2 Earnings Miss Estimates

by Zacks Equity Research

Assertio (ASRT) delivered earnings and revenue surprises of -7.14% and 3.57%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Rigel (RIGL) delivered earnings and revenue surprises of 50% and 3.34%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aquestive (AQST) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

Aquestive's (AQST) second-quarter 2023 revenues are likely to have been driven by rising licensed product revenues.

Zacks Equity Research

Assertio (ASRT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Assertio (ASRT) delivered earnings and revenue surprises of -153.85% and 12.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Assertio (ASRT) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Assertio (ASRT) closed at $5.08, marking a +1.6% move from the previous day.